The therapy targets patients who have suffered a heart attack, with reduced quality of life and life expectancy. The bioimplant initiates cellular mechanisms involved in tissue repair, significantly improving the patients' quality of life. The membrane used in PeriCord comes from the pericardium of a tissue donor, which is then decellularized, lyophilized, and recellularized with mesenchymal stem cells from umbilical cord donors.
Following the initial success, a broader clinical trial included 12 candidates for coronary bypass, comparing those treated with PeriCord against those without. The outcomes have further confirmed the safety and efficacy of this treatment, paving the way for its potential use in other areas of medicine involving tissue repair and inflammation.
MEDICA-tradefair.com; Source: Germans Trias i Pujol Research Institute (IGTP)